25 July 2017 / international
Debiopharm International SA Awarded $2.6 Million Grant from CARB-X to Support Development of Debio 1453 to fight drug resistant gonorrhea [Read more]
30 June 2017 / international
Debiopharm International SA and Arbor Pharmaceuticals, LLC Announce U.S. FDA Approval for Triptodur™, Triptorelin 6-month Formulation, in the Treatment of Central Precocious Puberty (CPP) [Read more]
28 June 2017 / international
GenePOC Announces an Exclusive Distribution Agreement with Cardinal Health covering the US market [Read more]
15 June 2017
Debiopharm International SA Announces Completion of Enrollment in Phase I/II Clinical Trial with Debio 1143 in SCCHN [Read more]
01 June 2017
Debiopharm International SA Announces Results from Phase I Dose-Escalation Study of Debio 1347/CH5183284 [Read more]
09 March 2017
Debiopharm International SA Appeals to the Supreme Court regarding Towa Pharmaceutical Co., Ltd. case [Read more]
27 June 2017
Challenge Debiopharm-Inartis récompense les six finalistes 2017 [Read more]
01 December 2016
Chemosensitization to Carboplatin and Paclitaxel by IAP Inhibitor Debio 1143 in Ovarian Cancer Cell Lines: Signature Identification for Potential Patient Stratification [Read more]
29 October 2016
Paclitaxel-Carboplatin With The Oral Iap Inhibitor Debio1143 In A Subset Of Patients With Recurrent Epithelial Ovarian Cancer (EOC): Phase I [Read more]
29 October 2016
The Staphylococcal-specific Antibiotic Debio 1450 Minimizes Disturbance to the Gut Microbiota in Mice [Read more]
